Academic Journal
Jiuwei Xiaozhi Decoction Alleviates High-Fat Diet-Induced MASLD by Suppressing Hepatic SREBP2-Driven Cholesterogenesis and Restoring PPARα-Mediated Fatty Acid Oxidation.
| Τίτλος: | Jiuwei Xiaozhi Decoction Alleviates High-Fat Diet-Induced MASLD by Suppressing Hepatic SREBP2-Driven Cholesterogenesis and Restoring PPARα-Mediated Fatty Acid Oxidation. |
|---|---|
| Συγγραφείς: | Ma Y; Shenzhen Hospital, Beijing University of Chinese Medicine, Shenzhen, China., Gao X; National Institute of TCM Constitution and Preventive Medicine, Beijing University of Chinese Medicine, Beijing, China., Wang J; National Institute of TCM Constitution and Preventive Medicine, Beijing University of Chinese Medicine, Beijing, China., Li L; National Institute of TCM Constitution and Preventive Medicine, Beijing University of Chinese Medicine, Beijing, China., Huang Z; Shenzhen Hospital, Beijing University of Chinese Medicine, Shenzhen, China., Li F; Shenzhen Hospital, Beijing University of Chinese Medicine, Shenzhen, China. |
| Πηγή: | Chemical biology & drug design [Chem Biol Drug Des] 2026 Aug; Vol. 108 (2), pp. e70371. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101262549 Publication Model: Print Cited Medium: Internet ISSN: 1747-0285 (Electronic) Linking ISSN: 17470277 NLM ISO Abbreviation: Chem Biol Drug Des Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Oxford : Wiley-Blackwell, 2006- |
| Ιατρικοί όροι (MeSH): | Drugs, Chinese Herbal*/pharmacology , Drugs, Chinese Herbal*/chemistry , Drugs, Chinese Herbal*/therapeutic use , PPAR alpha*/metabolism , Sterol Regulatory Element Binding Protein 2*/metabolism , Cholesterol*/metabolism , Cholesterol*/biosynthesis , Fatty Acids*/metabolism , Non-alcoholic Fatty Liver Disease*/drug therapy , Non-alcoholic Fatty Liver Disease*/metabolism , Fatty Liver*/drug therapy , Fatty Liver*/metabolism, Diet, High-Fat/adverse effects ; Liver/metabolism ; Liver/drug effects ; Liver/pathology ; Oxidation-Reduction/drug effects ; Lipid Metabolism/drug effects ; Animals ; Male ; Mice ; Molecular Docking Simulation ; Mice, Inbred C57BL ; Network Pharmacology |
| Περίληψη: | Jiuwei Xiaozhi Decoction (JWXZ) is a nine-herb traditional Chinese medicine formula clinically used for hepatic steatosis and dyslipidemia, but its chemical basis and pharmacological mechanisms in metabolic dysfunction-associated steatotic liver disease (MASLD) remain incompletely defined. The chemical profile of JWXZ was characterized by UHPLC-HRMS/MS. Its therapeutic effects were evaluated in a high-fat diet (HFD)-induced mouse model of MASLD, followed by hepatic transcriptomic analysis, network pharmacology, molecular docking, Western blotting, and immunofluorescence validation. UHPLC-HRMS/MS identified 178 chemical constituents in JWXZ, including phenolic acids, flavonoids, flavonoid glycosides, alkaloids, isoflavones, and coumarins. In HFD-fed mice, JWXZ attenuated body weight gain, white adipose accumulation, dyslipidemia, hepatic triglyceride and cholesterol accumulation, serum transaminase elevation, and hepatic steatosis, while improving glucose tolerance and partially restoring whole-body metabolic flexibility. Hepatic transcriptomics identified 124 HFD-dysregulated genes reversed by high-dose JWXZ, with prominent enrichment in cholesterol and sterol biosynthesis, endoplasmic reticulum proteostasis, oxidative stress response, and PPARα-related lipid handling. Integrated transcriptomic and network pharmacology analyses further identified 157 shared targets and 18 overlapping pathways, converging mainly on cholesterol metabolism and PPAR signaling. Protein-level validation showed that JWXZ suppressed SREBP2 proteolytic activation, reduced nuclear SREBP2 abundance, and downregulated HMGCR, SQLE, and PCSK9, indicating inhibition of the hepatic cholesterogenic program. In parallel, JWXZ restored nuclear PPARα abundance and CPT1A expression, consistent with reactivation of fatty acid oxidation. JWXZ also reduced hepatic EGFR phosphorylation and lowered hepatic and circulating TNF-α, IL-6, IL-1β, and MCP-1 levels. Molecular docking provided supportive evidence for potential interactions between representative JWXZ constituents and key regulators, including naringin-HMGCR, chlorogenic acid-SQLE, rhoifolin-PPARα, and rhoifolin-SREBP2. These findings suggest that JWXZ ameliorates HFD-induced MASLD mainly by rebalancing hepatic lipid metabolism through coordinated suppression of SREBP2-mediated cholesterogenesis and restoration of PPARα-mediated fatty acid oxidation, with associated attenuation of EGFR-linked inflammatory responses. (© 2026 The Author(s). Chemical Biology & Drug Design published by John Wiley & Sons Ltd.) |
| References: | Ann, J. Y., H. Eo, and Y. Lim. 2015. “Mulberry Leaves (Morus alba L.) Ameliorate Obesity‐Induced Hepatic Lipogenesis, Fibrosis, and Oxidative Stress in High‐Fat Diet‐Fed Mice.” Genes and Nutrition 10, no. 6: 46. https://doi.org/10.1007/s12263‐015‐0495‐x. Bao, X., Y. Liang, H. Chang, et al. 2024. “Targeting Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9): From Bench to Bedside.” Signal Transduction and Targeted Therapy 9, no. 1: 13. Barbhuiya, P. A., R. Yoshitomi, and M. P. Pathak. 2025. “Understanding the Link Between Sterol Regulatory Element Binding Protein (SREBPs) and Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD).” Current Obesity Reports 14, no. 1: 36. Carli, F., G. Della Pepa, S. Sabatini, A. V. Puig, and A. Gastaldelli. 2024. “Lipid Metabolism in MASLD and MASH: From Mechanism to the Clinic.” JHEP Reports 6, no. 12: 101185. Chandrasekaran, P., and R. Weiskirchen. 2024. “The Role of SCAP/SREBP as Central Regulators of Lipid Metabolism in Hepatic Steatosis.” International Journal of Molecular Sciences 25, no. 2: 1109. Cho, M. H., H. Jin, J. Ha, S. Chu, and S. An. 2025. “An Integrated Systems Pharmacology Approach Combining Bioinformatics, Untargeted Metabolomics and Molecular Dynamics to Unveil the Anti‐Aging Mechanisms of Tephroseris Flammea.” Biomolecules 15, no. 12: 1740. https://doi.org/10.3390/biom15121740. Choung, S., J. M. Kim, K. H. Joung, E. S. Lee, H. J. Kim, and B. J. Ku. 2019. “Epidermal Growth Factor Receptor Inhibition Attenuates Non‐Alcoholic Fatty Liver Disease in Diet‐Induced Obese Mice.” PLoS One 14, no. 2: e0210828. European Association for the Study of the Liver, European Association for the Study of Diabetes, and European Association for the Study of Obesity. 2024. “EASL‐EASD‐EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD): Executive Summary.” Diabetologia 67, no. 11: 2375–2392. https://doi.org/10.1007/s00125‐024‐06196‐3. Fan, Y., Q. Zhao, Y. Wei, et al. 2023. “Pingwei San Ameliorates Spleen Deficiency‐Induced Diarrhea Through Intestinal Barrier Protection and Gut Microbiota Modulation.” Antioxidants 12, no. 5: 1122. Guo, K., X. He, J. Zou, and Y. Tang. 2025. “Commentary: Pingwei Powder Alleviates High‐Fat Diet‐Induced Colonic Inflammation by Modulating Microbial Metabolites SCFAs.” Frontiers in Cellular and Infection Microbiology 15: 1709791. https://doi.org/10.3389/fcimb.2025.1709791. Harrison, S. A., P. Bedossa, C. D. Guy, et al. 2024. “A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH With Liver Fibrosis.” New England Journal of Medicine 390: 497–509. Harrison, S. A., T. Rolph, M. Knott, and J. Dubourg. 2024. “FGF21 Agonists: An Emerging Therapeutic for Metabolic Dysfunction‐Associated Steatohepatitis and Beyond.” Journal of Hepatology 81, no. 3: 562–576. He, J., Y. Yang, F. Zhang, et al. 2022. “Effects of Poria Cocos Extract on Metabolic Dysfunction‐Associated Fatty Liver Disease via the FXR/PPARα‐SREBPs Pathway.” Frontiers in Pharmacology 13: 1007274. https://doi.org/10.3389/fphar.2022.1007274. He, Y., Y. Chen, S. Qian, et al. 2025. “Immunopathogenic Mechanisms and Immunoregulatory Therapies in MASLD.” Cellular and Molecular Immunology 22, no. 10: 1159–1177. Jiang, S., C. Liang, X. Wan, et al. 2024. “Integrative Analysis Reveals the Anti‐Obesity Roles of Poria Cocos Polysaccharides Through Beneficial Effects on Gut Microbiota.” Journal of Functional Foods 119: 106308. Kong, C.‐Y., Z.‐M. Li, B. Han, et al. 2026. “Modulation of Gut Microbiota by Tangerine Peel Polysaccharide: A Promising Strategy for Obesity Management via Acetic Acid Production.” Food Research International 229: 118460. Krahmer, N., T. C. Walther, and R. V. Farese Jr. 2025. “The Pathogenesis of Hepatic Steatosis in MASLD: A Lipid Droplet Perspective.” Journal of Clinical Investigation 135, no. 18: e198334. https://doi.org/10.1172/jci198334. Lee, G. H., C. Peng, S. A. Park, et al. 2020. “Citrus Peel Extract Ameliorates High‐Fat Diet‐Induced NAFLD via Activation of AMPK Signaling.” Nutrients 12, no. 3: 673. Li, Y. S., C. Ni, J. Wang, et al. 2015. “Lecture 23: Discussion on Medical Cases of Fatty Liver.” Bulletin of Chinese Medicine 14, no. 5: 37 (in Chinese). Li, Z., J. Xu, P. Zheng, et al. 2015. “Hawthorn Leaf Flavonoids Alleviate Nonalcoholic Fatty Liver Disease by Enhancing the Adiponectin/AMPK Pathway.” International Journal of Clinical and Experimental Medicine 8, no. 10: 17295. Liu, D., C. C. Wong, Y. Zhou, et al. 2021. “Squalene Epoxidase Induces Nonalcoholic Steatohepatitis via Binding to Carbonic Anhydrase III and Is a Therapeutic Target.” Gastroenterology 160, no. 7: 2467–2482. https://doi.org/10.1053/j.gastro.2021.02.051. Luo, Y., Y. Zheng, J. Qin, et al. 2026. “Targeting the Cytokine‐Epigenetic Axis: A New Paradigm and Prospects for Disease Treatment.” European Cytokine Network 37, no. 2: 97–119. Miao, J., J. Lin, J. Dong, et al. 2024. “Discovery and Evaluation of Novel SHIP‐1 Inhibitors.” Bioorganic & Medicinal Chemistry 114: 117965. https://doi.org/10.1016/j.bmc.2024.117965. Miao, R., Y. Zhang, Y. Zhang, X. Fang, R. Yin, and J. Tian. 2025. “Jiangtang Tiaozhi Formula Ameliorates MASLD by Regulating Liver ABCD2/PEX2/ATGL Axis‐Mediated Fatty Acid Metabolic Reprogramming.” Phytomedicine 145: 157032. Nguyen, V., E. G. Taine, D. Meng, T. Cui, and W. Tan. 2024. “Chlorogenic Acid: A Systematic Review on the Biological Functions, Mechanistic Actions, and Therapeutic Potentials.” Nutrients 16, no. 7: 924. Ozkan‐Nikitaras, T., D. J. Grzesik, L. E. Romano, J. Chapple, P. J. King, and C. C. Shoulders. 2024. “N‐SREBP2 Provides a Mechanism for Dynamic Control of Cellular Cholesterol Homeostasis.” Cells 13, no. 15: 1255. Pengnet, S., P. Sumarithum, N. Phongnu, et al. 2022. “Naringin Attenuates Fructose‐Induced NAFLD Progression in Rats Through Reducing Endogenous Triglyceride Synthesis and Activating the Nrf2/HO‐1 Pathway.” Frontiers in Pharmacology 13: 1049818. Sanyal, A. J., P. N. Newsome, I. Kliers, et al. 2025. “Phase 3 Trial of Semaglutide in Metabolic Dysfunction‐Associated Steatohepatitis.” New England Journal of Medicine 392, no. 21: 2089–2099. Sheikh, M. Y., M. F. Younus, A. Shergill, and M. N. Hasan. 2025. “Diet and Lifestyle Interventions in Metabolic Dysfunction‐Associated Fatty Liver Disease: A Comprehensive Review.” International Journal of Molecular Sciences 26, no. 19: 9625. Sun, W., J. Jia, G. Liu, et al. 2025. “Polysaccharides Extracted From Old Stalks of Asparagus officinalis L. Improve Nonalcoholic Fatty Liver by Increasing the Gut Butyric Acid Content and Improving Gut Barrier Function.” Journal of Agricultural and Food Chemistry 73, no. 11: 6632–6645. Sun, W., N. Xue, and Q. Zhang. 2025. “Integrated Multi‐Omics Analysis Reveals the Mechanisms of Naringin in Ameliorating High‐Fat Diet‐Induced Metabolic Dysfunction‐Associated Steatotic Liver Disease.” Frontiers in Nutrition 12: 1694191. Tao, S.‐H., Y.‐Q. Lei, Y.‐M. Tan, Y.‐B. Yang, and W.‐N. Xie. 2024. “Chinese Herbal Formula in the Treatment of Metabolic Dysfunction‐Associated Steatotic Liver Disease: Current Evidence and Practice.” Frontiers in Medicine 11: 1476419. Venkatesan, N., L. C. Doskey, and H. Malhi. 2023. “The Role of Endoplasmic Reticulum in Lipotoxicity During Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) Pathogenesis.” American Journal of Pathology 193, no. 12: 1887–1899. Wu, Y., Z. Chen, Y. Hu, et al. 2026. “SUMOylation Regulates Tumorigenesis and Progression: Molecular Mechanisms and Therapeutic Applications.” Interdisciplinary Medicine 4, no. 3: e70120. https://doi.org/10.1002/inmd.70120. Yu, Y. Y., M. Feng, Y. Chen, et al. 2025. “Asprosin‐FABP5 Interaction Modulates Mitochondrial Fatty Acid Oxidation Through PPARα Contributing to MASLD Development.” Advanced Science (Weinheim, Baden‐Wurttemberg, Germany) 12, no. 21: 2415846. Zhao, N., M. Dang, Y. Sun, et al. 2025. “Integrated Chemical Composition, Transcriptomics, and Network Pharmacology to Reveal the Mechanism of Jia‐Wei‐Si‐Miao‐Yong‐An Decoction in ACS Model Rats.” Phytomedicine 145: 157027. Zheng, N., H. Wang, W. Zhu, Y. Li, and H. Li. 2024. “Astragalus Polysaccharide Attenuates Nonalcoholic Fatty Liver Disease Through THDCA in High‐Fat Diet‐Fed Mice.” Journal of Ethnopharmacology 320: 117401. Zhong, J., X. He, X. Gao, et al. 2023. “Hyodeoxycholic Acid Ameliorates Nonalcoholic Fatty Liver Disease by Inhibiting RAN‐Mediated PPARα Nucleus‐Cytoplasm Shuttling.” Nature Communications 14, no. 1: 5451. Zhou, X., Y. Zhuang, X. Liu, et al. 2023. “Study on Tumour Cell‐Derived Hybrid Exosomes as Dasatinib Nanocarriers for Pancreatic Cancer Therapy.” Artificial Cells, Nanomedicine, and Biotechnology 51, no. 1: 532–546. https://doi.org/10.1080/21691401.2023.2264358. Ziółkiewicz, A., P. Niziński, J. Soja, et al. 2024. “Potential of Chlorogenic Acid in the Management of Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD): Animal Studies and Clinical Trials—A Narrative Review.” Metabolites 14, no. 6: 346. Zou, J., Y. Dai, Y. Yu, Y. Wu, Q. Xiang, and R. Yu. 2026. “Integrated Analysis of Network Pharmacology and Multi‐Omics Reveals the Mechanisms of Zuogui Jiangtang Qinggan Formula Ameliorates MASLD via Fatty Acid Metabolic Reprogramming.” Phytomedicine 155: 158128. |
| Grant Information: | SZZYSM202205008 Medical and Health Three Famous Project (Sanming Project) of Shenzhen; JCYJ20230807150911023 Natural Science Foundation of Shenzhen Municipality; JCYJ20240813165130040 Natural Science Foundation of Shenzhen Municipality; LGWJ2024-29 Special Fund for Scientific and Technological Innovation of Shenzhen Longgang District |
| Contributed Indexing: | Keywords: Jiuwei Xiaozhi decoction; PPARα; SREBP2; hepatic lipid metabolism; metabolic dysfunction‐associated steatotic liver disease; network pharmacology; traditional Chinese medicine |
| Substance Nomenclature: | 0 (Drugs, Chinese Herbal) 0 (PPAR alpha) 0 (Sterol Regulatory Element Binding Protein 2) 97C5T2UQ7J (Cholesterol) 0 (Fatty Acids) |
| Entry Date(s): | Date Created: 20260729 Date Completed: 20260729 Latest Revision: 20260731 |
| Update Code: | 20260731 |
| PubMed Central ID: | PMC13416012 |
| DOI: | 10.1111/cbdd.70371 |
| PMID: | 42522177 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1747-0285 |
|---|---|
| DOI: | 10.1111/cbdd.70371 |